


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of:

Jacques DUMAS et al.

Serial No.: 09/458,014

Filed: December 10, 1999

Title: INHIBITION OF P38 KINASE USING ACTIVITY SUBSTITUTED
HETEROCYCLIC UREAS

Confirmation No.: 8328

Examiner: MITCHELL, Gregory W.

Group Art Unit: 1617


REPLY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the thirty day notice dated April 12, 2006, applicants revise the election of species, with traverse, as follows.


Applicants elect rheumatoid arthritis as a single disease and compound 104 as a single compound having the following formula:



The traversal is on the basis that the PTO has not established that it would pose an undue burden to examine the full scope of the application.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,


Richard J. Traverso, Reg. No. 30,595
Attorneys for Applicants

MILLEN, WHITE, ZELANO &
BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: BAYER-0011-C01

Date: March 12, 2006